Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence trial of Salmeterol/Fluticasone MDI HEXAL versus Seretide 50 in children with moderate persistent asthma
2007-000135-26Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone in asthma (2 arms), sponsored by Hexal AG. Primary endpoints: Change in FEV1 from baseline to end of treatment and Area under the 4-hour serial FEV1 curve. Started Apr 2007; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2007-000135-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000135-26.